

DATA MENGENAI PATEN ARV TERKAIT DUVIRAL

Sumber : <http://www.drugpatentwatch.com/ultimate/preview/ingredient/index.php?query=LAMIVUDINE;%20ZIDOVUDINE>

Summary for Generic Name: LAMIVUDINE; ZIDOVUDINE

Tradenames:	1
Patents:	4
Applicants:	1
NDA:	1
Therapeutic Class:	Antivirals

Tentative approvals for LAMIVUDINE; ZIDOVUDINE

Applicant	Application No.	Form	Dosage
—	—	TABLET; ORAL	150MG; 300MG; 200MG
—	—	TABLET; ORAL	150MG; 300MG; 200MG
—	—	TABLET; ORAL	150MG; 300MG; 300MG

Berikut adalah Paten Produksi [GlaxoSmithKline](#) untuk obat kombinasi lamivudine dan Zidovudine dengan merek Paten Combivir – Di indonesia merk dagang yang diproduksi oleh Kimia Farma adalah Duviral

Applicant	Tradename	Generic Name	NDA	Approval Date	Type	RLD	Patent Number	Product	Substance	Delist Req.	Patent Expiration	Exclusivity Expiration
Viiv Hlthcare	COMBIVIR	lamivudine; zidovudine	020857	Sep 26, 1997	RX	Yes	5,047,407*PED			Y	May 17, 2010	
Viiv Hlthcare	COMBIVIR	lamivudine; zidovudine	020857	Sep 26, 1997	RX	Yes	5,859,021	Y	Y		May 15, 2012	
Viiv Hlthcare	COMBIVIR	lamivudine; zidovudine	020857	Sep 26, 1997	RX	Yes	5,905,082*PED			Y	Nov 18, 2016	

Info Paten: 5,047,407*PED

Summary for Patent: 5,047,407*PED

Title: 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties

Abstract: Methods and compositions for preventing or treating human immunodeficiency virus (HIV) infections characterized by 2-substituted-5-substituted-1,3-oxathiolanes.

Inventor(s): Belleau; Bernard (Westmount, CA), Nguyen-Ba; Nghe (Brossard, CA)

Assignee: IAF BioChem International, Inc. (Montreal, CA)

Application Number: 07/308,101

Patent Claim Types: *Compound; Use; Composition;*

Applicant	Tradename	Generic Name	NDA	Approval Date	Type	RLD	Patent Number	Product	Substance	Delist Req.	Patent Expiration	Patex_Term
Viiv Hlthcare	EPZICOM	abacavir sulfate; lamivudine	021652	Aug 2, 2004	RX	Yes	5,047,407*PED			Y	May 17, 2010	
Viiv Hlthcare	TRIZIVIR	abacavir sulfate; lamivudine; zidovudine	021205	Nov 14, 2000	RX	Yes	5,047,407*PED			Y	May 17, 2010	
Viiv Hlthcare	EPIVIR	lamivudine	020596	Nov 17, 1995	RX	Yes	5,047,407*PED			Y	May 17, 2010	

Info Paten: 5,859,021

Summary for Patent: 5,859,021

Title: Antiviral combinations

Abstract: Combinations comprising a compound of formula (1) ##STR1## or a pharmaceutically acceptable derivative thereof and an inhibitor of HIV replication, pharmaceutical formulations thereof and their use in the treatment of HIV infections.

Inventor(s): Cameron; Janet Mary (Greenford, GB), Cammack; Nicholas (Greenford, GB)

Assignee: Glaxo Group Limited (Greenford, GB)

Application Number: 08/605,610

Patent Claim Types: *Compound; Composition; Use;*

applicant	Tradename	Generic Name	NDA	Approval Date	Type	RLD	Patent Number	Product	Substance	Delist Req.	Patent Expiration	Patex_Term
Viiv Hlthcare	COMBIVIR	lamivudine; zidovudine	020857	Sep 26, 1997	RX	Yes	5.859.021	Y	Y		May 15, 2012	TREATMENT OF HIV

Info Paten: 5,905,082*PED

Summary for Patent: 5,905,082*PED

Title: Crystalline oxathiolane derivatives

Abstract: (-)cis-4-Amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidine-2-on e in crystalline form, in particular as needle-shaped or bypyramidyl crystals, pharmaceutical formulations thereof, methods for their preparation and their use in medicine.

Inventor(s): Roberts; Tony Gordon (Ware, GB), Evans; Paul (Ware, GB)

Assignee: Glaxo Group Limited (Greenford, GB)

Application Number: 07/892,029

Patent Claim Types: *Composition; Formulation; Compound; Dosage form; Use;*

Applicant	Tradename	Generic Name	NDA	Approval Date	Type	RLD	Patent Number	Product	Substance	Delist Req.	Patent Expiration	Patex_Term
-----------	-----------	--------------	-----	---------------	------	-----	---------------	---------	-----------	-------------	-------------------	------------

Viiv Hlthcare	EPZICOM	abacavir sulfate; lamivudine	021652	Aug 2, 2004	RX	Yes	5.905.082*PED			Y	Nov 18, 2016	
Viiv Hlthcare	TRIZIVIR	abacavir sulfate; lamivudine; zidovudine	021205	Nov 14, 2000	RX	Yes	5.905.082*PED			Y	Nov 18, 2016	
Viiv Hlthcare	EPIVIR	lamivudine	020564	Nov 17, 1995	RX	No	5.905.082*PED			Y	Nov 18, 2016	